SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jun 2, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The SNU IBD Cohort Study is an important research project aimed at understanding who is more likely to develop Inflammatory Bowel Disease (IBD). Researchers want to find out what specific characteristics or risk factors might increase a person's chance of getting this condition. To do this, they will compare people who are at high risk for IBD, such as those with family members who have it or those with certain autoimmune diseases, to healthy individuals and those already diagnosed with IBD.
If you or someone you know is a first-degree relative of an IBD patient or has an autoimmune disease, you may be eligible to participate in this study. Participants will fill out questionnaires to track any symptoms, undergo blood tests and stool tests, and may have a colonoscopy if needed for regular health checks. This study is currently recruiting participants of all genders aged 36 to 52. It’s a chance to contribute to important research that could help identify who is at risk for IBD and how to better manage it in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • first-degree relatives of Inflammatory Bowel Disease patients
- • patients who are diagnosed with autoimmune diseases
- • patients with functional gastrointestinal disorders who are ASCA-positive
- Exclusion Criteria:
- • Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded.
- • Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer.
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported